• 1
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 928.
  • 2
    Kelly K, Crowey J, Bunn PA, Livingston RB, Gandara DR. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): Southwest Oncology Group (SWOG) trial. Proc Am Soc Clin Oncol 1999; 18: 461.
  • 3
    Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001; 92: 263947.
  • 4
    Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vachonikolis I. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. Lancet 2001; 357: 147884.
  • 5
    Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajer OL, Cherard MP, Rio MC, Chamborn P. A novel metalloproteinases gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699704.
  • 6
    Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998; 82: 135963.
  • 7
    Murrer D, Breathnach R, Engelman A, Millon R, Bronner G, Flesch H, Dumont P, Eber M, Abecasis J. Expression of collagenase related metalloproteinases genes in human lung or head and neck tumors. Int J Cancer 1991; 48: 5506.
  • 8
    Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000; 17: 67381.
  • 9
    Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA. Elevated levels of Mw 92,000 type IV collagenase in brain tumors. Cancer Res 1993; 53: 220811.
  • 10
    Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 4612.
  • 11
    Brown PD, Bloxidge RE, Stuart NSE, Gatter KC, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85: 5748.
  • 12
    Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 7907.
  • 13
    Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19: 664250.
  • 14
    Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 17893.
  • 15
    Dy GK, Haluska P, Adjei AA. Novel pharmacological agents in clinical development for solid tumors. Expert Opin Investig Drugs 2001; 10: 205988.
  • 16
    Yamada A, Uegaki A, Nakamura T, Ogawa K. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res 2000; 49: 1446.
  • 17
    Nozaki S, Sissons S, Cassaza AM, Sledge GW. Inhibition of human breast cancer regrowth and pulmonary metastasis by BAY 12-9566 in athymic mice. Proc Am Assoc Cancer Res 1998; 39. Abstract nr 2053
  • 18
    Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 1999; 878: 23670.
  • 19
    Verheijen JH, Nieuwenbroek NM, Beekman B, Hanemaaijer R, Verspaget HW, Ronday HK, Bakker AH. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J 1997; 323: 6039.
  • 20
    Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth-inhibitory lymphokines. J Immunol Methods 1984; 70: 25768.
  • 21
    Ikeda M, Maekawa R, Tanaka H, Matsumoto M, Yoshioka T. Inhibition of gelatinolytic metalloproteinases inhibitor: application of film in situ zymography. Clin Cancer Res 2000; 6: 32906.
  • 22
    Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000; 157: 1893903.
  • 23
    Tsunezaki Y, Kinoh H, Takino T, Watanabe Y, Okada Y, Shinagawa A, Sato H, Seiki M. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 1996; 56: 567883.
  • 24
    Smylie M, Mercier R, Aboulafia D, Tucker R, Bonomi P, Collier M, Rose Keller M, Stuart-Smith J, Knowles M, Clendeninn NJ, Shepherd F. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20: Abstr. 1926.
  • 25
    Shepherd FA, Giaccone G, Debruyne C, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Zee B, Sadura A, Seymour L. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC study. Proc Am Soc Clin Oncol 2001; 20:Abstr. 11.
  • 26
    Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJ, Huxley P, Laber D, Mccourt M, Whittaker M, Wood LM, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann NY Acad Sci 1999; 878: 22835.
  • 27
    Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 344755.
  • 28
    Haq M, Shafii A, Zervos EE, Rosemurgy A. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res 2000; 60: 320711.
  • 29
    Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 113549.
  • 30
    Wielockx B, Lannoy K, Shapiro SD, Itoh T, Itohara S, Vandekerckhove J, Libert C. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 2001; 7: 12028.
  • 31
    Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JWL. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002; 86: 186470.